VSIR

V-type immunoglobulin domain-containing suppressor of T-cell activation

7,290 patent compounds predicted against VSIR, 2,264 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL205664	0.62	14/20
SCHEMBL206075	0.63	12/20
SCHEMBL2945766	0.62	10/20
SCHEMBL2942666	0.67	9/20
SCHEMBL2943147	0.48	9/20
SCHEMBL4474314	0.60	8/20
SCHEMBL6381122	0.57	8/20
SCHEMBL2950004	0.56	8/20
SCHEMBL2949787	0.56	8/20
SCHEMBL2941655	0.50	8/20
SCHEMBL2949229	0.46	8/20
SCHEMBL2950570	0.45	8/20
SCHEMBL2942671	0.53	7/20
SCHEMBL2949312	0.53	7/20
SCHEMBL2941593	0.51	7/20
SCHEMBL2948346	0.48	7/20
SCHEMBL2949248	0.48	7/20
SCHEMBL2947490	0.48	7/20
SCHEMBL2947492	0.48	7/20
SCHEMBL2940607	0.47	7/20

Germline variants in VSIR on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full VSIR gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to VSIR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease	PHASE4	UNKNOWN
Understanding the Immune Response to Two Different Meningitis Vaccines	PHASE4	COMPLETED
A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency	PHASE4	COMPLETED
V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency	PHASE3	RECRUITING
A Clinical Study of Intravenous Immunoglobulin	PHASE3	COMPLETED
ZyVac-TCV Bangladesh Study	PHASE3	NOT_YET_RECRUITING
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency	PHASE3	COMPLETED
Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)	PHASE3	COMPLETED
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation	PHASE2	UNKNOWN
Effects on Microcirculation of IgGAM in Severe Septic/Septic Shock Patients.	PHASE2	COMPLETED
Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency	PHASE1/PHASE2	COMPLETED
Llama Antibody, Rotavirus Diarrhoea, Children	PHASE2	COMPLETED
Dose Escalation Trial of CD40.HIVRI.Env Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers	PHASE1	COMPLETED
Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine	PHASE1	COMPLETED
A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors	PHASE1	COMPLETED
68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis	EARLY_PHASE1	UNKNOWN
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)	nan	NOT_YET_RECRUITING
VDJ-recombination of the B-cell Receptor Following Hematopoietic Stem Cell Transplantation	nan	NOT_YET_RECRUITING
GLILD Diagnosed in Children and Young Adults With Common Variable Immunodeficiency	nan	UNKNOWN
Impaired Secretory IgA and Mucosal Immunity in Cystic Fibrosis	nan	UNKNOWN
Impact of Seasonal Malaria Chemoprevention on Immunity Against Malaria Among Children in Northern Benin	nan	COMPLETED
Angiogenesis and Fibrosis in Aortic Stenosis	nan	COMPLETED
High Definition Profiling of Ovarian Cancer Ascites	nan	NOT_YET_RECRUITING
Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors	nan	NOT_YET_RECRUITING
Role of Neutrophil Activation in Anaphylaxis to Neuro-Muscular Blocking Agents	nan	COMPLETED
Non-invasive Tumor Immunoglobulin Gene Next Generation Sequencing (IgNGS) in Diffuse Large B Cell Lymphoma (DLBCL)	nan	UNKNOWN
Immune Checkpoints in Predicting Response to Neoadjuvant Therapy in Rectal Cancer	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a VSIR binder may also engage these)

Protein	Name	Similarity
Q9D659	—	1.000	Q9D659 →
Q8R4V1	—	0.998	Q8R4V1 →
P26896	—	0.994	P26896 →
P16297	—	0.994	P16297 →
Q8N386	—	0.993	Q8N386 →
Q38J84	—	0.993	Q38J84 →
Q8BLR5	—	0.992	Q8BLR5 →
Q6AXU5	—	0.992	Q6AXU5 →
Q8K1T1	—	0.991	Q8K1T1 →
Q8NET5	—	0.991	Q8NET5 →
Q96PD2	—	0.990	Q96PD2 →
Q8CFD9	—	0.989	Q8CFD9 →
Q01151	—	0.989	Q01151 →
Q8BHW9	—	0.989	Q8BHW9 →
A1KXC4	—	0.989	A1KXC4 →
P98162	—	0.989	P98162 →
O14931	—	0.989	O14931 →
Q8BWG4	—	0.988	Q8BWG4 →
T1NXB5	—	0.988	T1NXB5 →
Q8MJ02	—	0.988	Q8MJ02 →
Q9Y426	—	0.988	Q9Y426 →
Q64322	—	0.988	Q64322 →
Q80UW3	—	0.988	Q80UW3 →
A6QQC6	—	0.988	A6QQC6 →
P61483	—	0.988	P61483 →
Q86UW2	—	0.988	Q86UW2 →
Q9D8D0	—	0.987	Q9D8D0 →
A8MVW5	—	0.987	A8MVW5 →
Q7TSF4	—	0.987	Q7TSF4 →
P61484	—	0.987	P61484 →